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Abstract
Background
Despite elimination efforts, the number of Mycobacterium leprae (M. leprae) infected individ-
uals who develop leprosy, is still substantial. Solid evidence exists that individuals living in
close proximity to patients are at increased risk to develop leprosy. Early diagnosis of lep-
rosy in endemic areas requires field-friendly tests that identify individuals at risk of develop-
ing the disease before clinical manifestation. Such assays will simultaneously contribute to
reduction of current diagnostic delay as well as transmission. Antibody (Ab) levels directed
against the M.leprae-specific phenolic glycolipid I (PGL-I) represents a surrogate marker for
bacterial load. However, it is insufficiently defined whether anti-PGL-I antibodies can be uti-
lized as prognostic biomarkers for disease in contacts. Particularly, in Bangladesh, where
paucibacillary (PB) patients form the majority of leprosy cases, anti-PGL-I serology is an
inadequate method for leprosy screening in contacts as a directive for prophylactic
treatment.
Methods
Between 2002 and 2009, fingerstick blood from leprosy patients’ contacts without clinical
signs of disease from a field-trial in Bangladesh was collected on filter paper at three time
points covering six years of follow-up per person. Analysis of anti-PGL-I Ab levels for 25 con-
tacts who developed leprosy during follow-up and 199 contacts who were not diagnosed
with leprosy, was performed by ELISA after elution of bloodspots from filter paper.
Results
Anti-PGL-I Ab levels at intake did not significantly differ between contacts who developed
leprosy during the study and those who remained free of disease. Moreover, anti-PGL-I
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serology was not prognostic in this population as no significant correlation was identified
between anti-PGL-I Ab levels at intake and the onset of leprosy.
Conclusion
In this highly endemic population in Bangladesh, no association was observed between
anti-PGL-I Ab levels and onset of disease, urging the need for an extended, more specific
biomarker signature for early detection of leprosy in this area.
Trial registration
ClinicalTrials.gov ISRCTN61223447
Author summary
Leprosy is an infectious disease caused by the bacterium Mycobacterium leprae, which
causes skin and nerve damage. Despite worldwide efforts to eliminate leprosy, the number
of infected individuals who develop leprosy, is still substantial. Household contacts of new
leprosy patients are especially at risk. Early diagnosis of leprosy is key in preventing life-
long handicaps as well as transmission. This requires field-friendly tests that identify indi-
viduals at risk of developing the disease before they develop clinical symptoms so that
they can receive (prophylactic) treatment. Measuring antibody levels directed against the
M.leprae-specific phenolic glycolipid I (PGL-I) provides an indication of the bacterial
load. To identify whether anti-PGL-I Ab levels correlate with the development of leprosy
in contacts of newly diagnosed leprosy cases, we analyzed these levels in 25 contacts who
developed leprosy during 6 years of follow-up and 199 contacts who were not diagnosed
with leprosy at 3 time points in 6 years. This study showed that anti-PGL-I Ab levels at
intake did not significantly differ between contacts who developed leprosy during the
study and those who remained free of disease. Therefore, anti-PGL-I Ab levels alone do
not represent a practical tool for prediction of which household contacts will develop lep-
rosy in an endemic area such as Bangladesh, with high levels of patients with paucibacil-
lary leprosy. This stresses the need for a diagnostic test composed of a biomarker
signature consisting of multiple biomarkers.
Introduction
Leprosy is an infectious disease caused by Mycobacterium leprae (M. leprae), which causes
damage to the skin and peripheral nerves[1]. The highest numbers of new leprosy cases are
detected in India (127,326 in 2015), Brazil (26,395 in 2015) and Indonesia (17,202 in 2015)[2].
Bangladesh also has highly endemic areas, with a number of new cases of above 3,000 per year
[2]. Although leprosy prevalence has decreased tremendously along with the widespread avail-
ability of multidrug therapy (MDT) in endemic areas, detection of new cases worldwide has
shown only a modest decline in the last five years, and has stabilized in some countries[3]. In
Bangladesh, the number of new cases was 3,976 in 2015, compared to 3,848 new cases in 2010
[2]. Indirect evidence indicates that worldwide millions of unreported cases linger undetected
as a gradual result of a decline in leprosy control activities after the disease was declared elimi-
nated[1]. The continued transmission is probably largely due to M. leprae infected individuals,
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carrying substantial numbers of bacteria but (yet) lacking clinical symptoms. Thus, early detec-
tion and subsequent (prophylactic) treatment of asymptomatically infected individuals as well
as subclinical disease is essential to reduce transmission.
Diagnosis of leprosy is still largely dependent on clinical signs and symptoms and detection
of acid fast bacteria. However, user friendly lateral flow assays provide new possibilities for
rapid diagnosis of leprosy patients in early stages of the disease or of M. leprae infected individ-
uals without any symptoms[4, 5]. Such assays are likely to contribute to reduction of current
diagnostic delay in endemic areas and also aid classification of leprosy disease, allowing appro-
priate treatment. Currently, there is no specific and sensitive test available that can detect
asymptomatic M. leprae infection or predict progression to clinical disease[6]. In view of the
long incubation time of leprosy (typically 3–5 years) as well as its low incidence, identification
of predictive biomarkers requires longitudinal monitoring of M. leprae-specific immunity in
those at risk of developing disease. Therefore, investments in large-scale longitudinal follow-
up studies, allowing intra-individual comparison of immune profiles in leprosy patients’ con-
tacts, is essential to evaluate which markers correlate with progression to disease and may be
used as predictive biomarkers.
M. leprae phenolic glycolipid I (PGL-I) is an extensively studied antigen on the outer sur-
face of the mycobacterium[7]. The existence of high levels of IgM antibodies to PGL-I[5–7],
has allowed the development of several tests that were investigated broadly for diagnostic pur-
poses[7–10]. Although useful for identifying multibacillary (MB) leprosy patients, anti-PGL-I
antibody (Ab) titers have little value in detecting PB leprosy patients, since the latter develop
cellular rather than humoral immunity and therefore often lack antibodies to PGL-I5.
In a previously conducted cluster randomized controlled trial, designated the COLEP
study, the effect of single dose rifampicin versus placebo in preventing leprosy in close contacts
of newly diagnosed leprosy patients was studied between 2002 and 2009 in a leprosy endemic
area in the Northwest of Bangladesh[11, 12]. To investigate whether anti-PGL-I Ab seroposi-
tivity can be used as a predictive biomarker for progression to leprosy in contacts, the current
study compared anti-PGL-I Ab levels of the prospective cohort at intake and at three time
points covering six years of follow-up per contact.
Methods
Study participants
Contacts of leprosy patients were voluntarily recruited as part of the COLEP study (a cluster
randomized controlled trial) in 2002 and 2003 in the districts Rangpur and Nilphamari in
the northwest of Bangladesh, which is a leprosy endemic area[11, 12]. Eligible participants
(patients and contacts) were informed verbally about the study and invited to participate.
Written consent was obtained from all participants at recruitment or from the parent or
guardian of under 18s. Contacts were followed prospectively from 2002/2003 to 2008/2009 for
the development of leprosy. Blood samples were collected by spotting on Whatman filter
paper (Sigma) and subsequently stored at -80˚C. Blood samples were collected at 4 time points:
recruitment into the study, follow-up 1 (FU1; two years after intake), follow-up 2 (FU2; four
years after intake) and follow-up 3 (FU3; six years after intake)[12]. Leprosy was diagnosed
when at least one of the following signs was present: one or more skin lesions with sensory
loss, thickened peripheral nerves, or a positive skin smear result for acid-fast bacilli. Patients
with negative smear results and no more than five skin lesions were classified as PB leprosy,
and those with a positive smear or more than five skin lesions as MB leprosy[12]. Clinical and
demographic data was collected in the COLEP study database[11].
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Test group selection
A random sample was taken from 28,092 contacts of leprosy patients recruited within the
COLEP study[11]. A total of 239 contacts developed leprosy within the six years of follow-
up. 25 contacts were included into this sub-study who were diagnosed with leprosy at either
FU1, FU2 or FU3 and for whom filter papers of at least three different time points were avail-
able. Out of the contacts who did not develop leprosy, 199 were randomly included using the
RAND formula (Excel 2010), aiming for an equal ratio of three age groups (0–14, 15–29, and
30+ years).
The COLEP study represents a unprecedented field trial for leprosy, because it includes
valuable longitudinal analysis of contacts and thus is uniquely suited to identify the predictive
value of biomarkers. However, the COLEP study did not collect blood samples from contacts
as the only samples collected was blood on filter paper. Therefore, this limited biomarker anal-
ysis to anti-PGL-I Ab only.
Leprosy prevalence
In this part of the country, the new case detection rate of leprosy was 3.21 per 10,000 in 2002
(DBLM Annual Report 2002). In these cases leprosy was diagnosed by active and passive case
detection. In 2002 and 2003 random samples from the general population were taken to calcu-
late the prevalence of previously undiagnosed leprosy (PPUL). In the contact group of the
COLEP study, the PPUL rate was 73/10,000, compared to 15.1/10,000 in the samples taken
from the general population. These cases were found by active door-to-door screening[13].
Synthetic PGL-I
Disaccharide epitope (3,6-di-O-methyl-β-D-glucopyranosyl(1!4)2,3-di-O-methylrhamno-
pyranoside) of M. leprae specific native PGL-I glycolipid was synthesized and coupled to
human serum albumin (synthetic PGL-I; designated ND-O-HSA). This was generated with
support from the NIH/NIAID Leprosy Contract N01-AI-25469 and obtained through the Bio-
defense and Emerging Infections Research Resources Repository (http://www.beiresources.
org/TBVTRMResearchMaterials/tabid/1431/Default.aspx).
PGL-I ELISA
Antibodies (IgM, IgG, IgA) against M. leprae PGL-I were detected as described previously[5,
14, 15]. ND-O-HSA was coated onto high-affinity polystyrene Immulon 4HBX 96-well Nunc
ELISA plates (Thermo Scientific, Rochester, NY) using 500 ng per well in 50 μl of 0.1M sodium
carbonate/bicarbonate pH 9.6 (i.e. coating buffer) at 4˚C overnight. Unbound antigen was
removed by washing six times with PBS (phosphate buffered saline) with 0,05% Tween 20
(wash buffer). The wells were blocked with PBS containing 1% BSA (bovine serum albumin)
(Roche Diagnostics, Germany) for 1 hour at room temperature (RT). Bloodspots were
punched from filter papers. Three punches (2 mm each) per individual were added to 100 μl
PBST (PBS/0,1% Tween20) and incubated at 4˚C in 24 wells plates. After overnight incuba-
tion, 50 μl PBST/NRS (PBST + 10% normal rabbit serum) was added to each well and the
plates were shaken gently for 1 hour at RT. The eluate was added to the ELISA plates (50 μl/
well) and incubated for 2 hours at RT. After incubating with the primary antibody, the wells
were washed six times with PBS with 0.05% Tween 20 (wash buffer), followed by the addition
of 50 μl of a 1:8,000 dilution of the secondary antibody anti-human (Dako P0212) for two
hours. Following washing the wells with the wash buffer six times, 50 μl of p-nitrophenylpho-
sphate substrate (Kirkegaard and Perry Labs, Gaithersburg, MD) was added. Antibodies (IgM,
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IgG, IgA) against M. leprae PGL-I were detected as previously described[14]. Absorbance was
determined at a wavelength of 450 nm. Samples with an optical density at 450 nm (OD450),
after correction for background OD above 0.150, were considered positive. This threshold was
determined by a threefold multiplication of an average EC value.
As quality control, anti-PGL-I IgM levels were determined for 10 Dutch leprosy patients by
ELISA using serum as well as blood spots on filter paper: Although IgM levels were higher for
9 individuals in sera, all seropositive individuals were also positive using blood spots and
OD450 values correlated well (R
2 = 0,80).
Statistical analyses
Multivariable logistic regression was used to calculate adjusted odds ratios for the level of ant-
PGL-I Ab levels at intake, and corrected for age and sex. A p-value 0.05 was used as a cut-off
for statistical significance. To investigate the association of changes in anti-PLG-I Ab from
baseline to the time of development of leprosy, generalized linear mixed models were used.
The dependent variable was the development of leprosy at a time point and the differences in
anti-PLG-I Ab levels from baseline were included as independent variables. To adjust for the
correlation between intra-individual measurements we included a random intercept for each
subject. The difference between the anti-PGL-I Ab levels between contacts of MB or PB index
patients was calculated using a t-test comparing averages. All analyses were performed in R
version 3.2.0 (R, Vienna, Austria; https://www.R-project.org).
Results
From the 28,092 contacts of leprosy patients recruited within the COLEP study[11], 239 con-
tacts developed leprosy within the six years of follow-up. For 25 contacts who were diagnosed
with leprosy during follow-up and 199 contacts who remained free of leprosy, good quality fil-
ter paper was available for at least three different time points during follow-up.
Characteristics of the study populations are shown in Table 1 and Table 2. Of the 25 con-
tacts who developed leprosy, 10 contacts developed leprosy at 2 years after intake (FU1), 7
Table 1. Contact characteristics.
Contacts who developed leprosy
(n = 25)
Contacts who did not develop leprosy
(n = 199)
Male 14 91
Female 11 108
Age (1–15 years) 8 65
Age (16–30
years)
9 54
Age (31+ years) 8 80
Leprosy at FU1 11 0
Leprosy at FU2 7 0
Leprosy at FU3 7 0
MB 4 0
PB 21 0
Characteristics of the contacts of new leprosy patients that either developed (n = 25) or did not (n = 199)
develop leprosy. Sex, age group, time point of leprosy development (FU1: two years after intake; FU2: four
years after intake; FU3: six years after intake) and type of leprosy developed (MB: multibacillary leprosy; PB:
paucibacillary leprosy) were specified.
https://doi.org/10.1371/journal.pntd.0006083.t001
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contacts at 4 years after intake (FU2) and 8 contacts at 6 years after intake (FU3). Four contacts
(16%) developed MB leprosy and 21 (84%) developed PB leprosy. This is the same proportion
of MB versus PB as in the total group of new leprosy cases diagnosed within the COLEP study
[12] 4 years after intake (24 MB contacts versus 126 PB contacts; 16% versus 84%). The group
was evenly distributed for sex (M/F = 1.17:1) and age categories. For 10 contacts the index
patient had MB leprosy, whereas for 15 contacts this was PB leprosy.
The anti-PGL-I Ab levels at intake were compared between the two groups of contacts (Fig
1). In the group of contacts who developed leprosy, the average anti-PGL-I Ab titer at intake
was 0.11, and varied between zero and 0.424. 6 of these 25 (24%) contacts who developed lep-
rosy had a positive anti-PGL-I Ab level of>0.150 at intake. In the group who did not develop
leprosy, the average anti-PGL-I Ab titer was 0.10 and varied between zero and 1.275. 35 out of
199 (17.6%) contacts who did not develop leprosy had a positive anti-PGL-I Ab level of>0.15
at intake. No significant association was observed for the anti-PGL-I Ab levels at baseline (OR:
1.01 (0.78, 1.31), 95% CI p = 0.94) between the two groups.
To further analyze the longitudinal pattern of PGL-I serology in contacts, the anti-PGL-I
Ab levels are depicted at different follow-up times, comparing the titers of contacts developing
leprosy (Fig 2A) to the titers of contacts without leprosy (Fig 2B). The difference between anti-
PGL-I Ab level at diagnosis was compared to the anti-PGL-I Ab level at intake. This difference
Table 2. Ridley Jopling classification of contacts with leprosy.
Ridley-Jopling Classification Contacts with PB leprosy (n = 21) Contacts with MB leprosy (n = 4)
I 1 0
TT 3 0
BT 17 4
Ridley-Jopling classification of contacts (n = 25) of new leprosy patients who developed leprosy at follow-up.
Contacts developed either paucibacillary leprosy (PB): indeterminate (I), tuberculoid (TT) or borderline
tuberculoid (BT) leprosy; or multibacillary leprosy (MB): borderline tuberculoid (BT) leprosy.
https://doi.org/10.1371/journal.pntd.0006083.t002
Fig 1. Cross-sectional analysis of anti-PGL-I Ig antibody levels at intake. Anti-PGL-I antibodies at intake
for contacts of leprosy patients who developed leprosy during the study (black circle; n = 25) and contacts who
remained free of leprosy disease (white box; n = 198) were detected by ELISA using natural disaccharide of
PGL-I linked to HSA (ND-O-HSA). Optical density readings were performed at 450nm (OD450) and corrected
for background levels. Median values per group are indicated by horizontal lines. The cut-off for positivity is
indicated by the dashed horizontal line.
https://doi.org/10.1371/journal.pntd.0006083.g001
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was minus 0.047, indicating that the level of anti-PGL-I Ab titer was lower at time of diagnosis
compared to time of intake. Next we calculated the difference between anti-PGL-I Ab titer at
various time points of follow-up to the anti-PGL-I Ab level at intake of the contacts who did
not develop leprosy using a generalized linear mixed model analysis. Thus, for all contacts who
did not develop leprosy, we compared the anti-PGL-I Ab level at FU1 to intake, the level of
FU2 to intake and the level at FU3 to intake. If a contact developed leprosy at FU2 (or FU3),
we also included the difference between anti-PGL-I Ab titer at FU1 (and FU2) and intake into
the group of contacts who did not develop leprosy. Differences in anti-PGL-I Ab levels had no
significant association with the development of leprosy at either of the three follow-up time
points (OR: 0.62 (0.15, 2.62), p = 0.52). Thus changes in anti-PLG-I Ab levels are not predictive
of disease progression in contacts of new leprosy patients in Bangladesh. Since MB patients
harbor a higher quantity of bacteria than PB, we separately considered the longitudinal pattern
of the anti-PGL-I Ab levels in the four contacts who developed MB leprosy (Fig 2C). The mean
OD450 at the time of diagnosis for both MB/BT and PB patients was below threshold for posi-
tive (< 0.15). Also, no increase in anti-PGL-I Ab levels was observed at the moment of leprosy
diagnosis; actually, anti-PGL-I Ab levels were often even lower at diagnosis time compared to
intake. The findings indicate that not only for newly diagnosed PB, but also for MB patients,
anti-PGL-I Ab levels do not represent a practical tool for prediction of leprosy.
Discussion
Although several studies described that positive anti-PGL-I Ab titers in household contacts of
leprosy patients were related to a higher risk of developing leprosy[16–19], reports also indi-
cated that more than half of the individuals with antibodies against PGL-I will never develop
leprosy[16, 17]. Besides, diagnosis based only on seropositivity for anti-PGL-I Abs would leave
more than half of the new leprosy cases undetected[16, 18, 19]. To study the value of anti
Fig 2. Longitudinal analysis of anti-PGL-I Ig antibody levels. Anti-PGL-I antibodies for all contacts of leprosy patients who developed leprosy
during the study (A; n = 25) and contacts who remained free of leprosy disease (B; n = 199) and 4 contacts who developed MB leprosy (C; n = 4)
were determined by ELISA using natural disaccharide of PGL-I linked to HSA (ND-O-HSA). Sera were tested at three follow-up time points; FU1: 2
years after intake, FU2: 4 years after intake, FU3: 6 years after intake. Optical density readings were performed at 450nm (OD450) and corrected for
background levels. Anti-PGL-I Ab levels at the time point of leprosy diagnosis are indicated with black circles (A and C). The cut-off for positivity is
indicated by the dashed horizontal lines.
https://doi.org/10.1371/journal.pntd.0006083.g002
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PGL-I Ab as a predictor of leprosy in those at risk of developing leprosy in a highly endemic
area, we here analyzed the anti PGL-I Ab levels in the blood of 224 contacts of leprosy patients
in the Northwest part of Bangladesh. However, no association was found between anti-PGL-I
Ab levels and onset of disease in this population.
As part of a variety of studies investigating the use of serology for prediction of leprosy in
those at risk of developing disease, a study in the state of Minas Gerais, Brazil[18] suggested
that anti-PGL-I serology in household contacts of leprosy patients can be used to identify lep-
rosy at a preclinical stage. This study identified more contacts with suspected leprosy in the
group with positive anti-PGL-I levels (9.62%) than in the test-negative group (1.76%). How-
ever, out of the 52 contacts with positive anti-PGL-I serology, only 5 had leprosy. The anti-
PGL-I seropositivity was higher in those contacts exposed to patients with MB leprosy than PB
leprosy, which is probably due to the higher bacterial load in MB patients and therefore higher
exposure rates of their contacts.
In another Brazilian study[17], performed in Rio de Janeiro, leprosy diagnosis had a strong
association with anti-PGL-I seropositivity at intake. A significantly higher proportion of
healthy contacts with anti-PGL-I Abs (5.6%) developed leprosy during the follow-up period
compared with those without (2.3%). Anti-PGL-I seropositive contacts had a 3.2-fold higher
risk of developing leprosy compared with seronegative contacts.
A third study performed in Cebu (the Philippines)[16] showed that household contacts of
MB leprosy patients with anti-PGL-I Abs have a 7.65-fold-higher risk of developing leprosy in
the six years of active surveillance than seronegative contacts. It is noteworthy that out of the
27 contacts developing leprosy, 13 remained seronegative, indicating that half of the new lep-
rosy cases would not be detected when solely anti-PGL-I serology would be used as a predictive
diagnostic tool. This particularly applies to PB cases, as all of the 10 newly diagnosed MB
patients were or became seropositive. On the other hand, 85 out of the 99 anti-PGL-I Ab posi-
tive contacts never developed leprosy, implying a false positivity rate of 86% when using anti-
PGL-I serology as a predictive marker for leprosy.
Barretto et al.[20] showed that the odds of seropositive versus seronegative school children
developing leprosy within two years is 2.7 times higher in an hyperendemic region in the Ama-
zones of Brazil (State of Para´). Thus, this would indicate a> 90% probability of detecting at
least one new case among 10 seropositive individuals in 2 years. On the other hand, 5 of 11
new cases found amongst school children in these high-risk areas in Brazil tested negative for
anti-PGL-I Abs. Furthermore, no significant difference between the median anti-PGL-I Ab
titer of new cases and of healthy school children was observed. Of note is that a significant
increase in the anti-PGL-I IgM titers was found at the time of diagnosis compared to intake.
The group that did not develop leprosy also demonstrated an increase in their average anti-
body titers, although the most significant increase was observed in the group that developed
disease. These findings in Brazil stand in contrast to our current study in Bangladesh, in which
hardly any difference or even a slight decrease in the anti-PGL-I Ab levels was observed in the
contacts who developed leprosy.
A recent meta-analysis among household contacts of new leprosy patients in French Poly-
nesia, Zaire, Papua New Guinean, Venezuela, Brazil, India and Philippines[19] shows that the
risk of developing leprosy is about three times higher in those who are positive for anti-PGL-I
Abs compared to the seronegative group, with the odds ratio varying from 2.72 to 3.53. How-
ever, the sensitivity of anti-PGL-I Ab tests as predictor of the development of clinical leprosy
was found to be lower than 50% in all studies. Thus, selecting contacts with anti-PGL-I anti-
bodies for prophylaxis, although possibly beneficial for reduction of transmission, would only
prevent less than half of the leprosy cases among contacts. Our findings in contacts in Bangla-
desh are in line with those of the meta-analysis by Penna et al.[19] as well as the other studies
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discussed above, since development of leprosy was not associated with the level of anti-PGL-I
seropositivity at intake, clearly indicating that also in Bangladesh anti-PGL-I Ab tests lack the
ability to early diagnose leprosy amongst leprosy contacts[21–23], if used as a stand alone tool.
Most of the leprosy patients’ contacts in our study developed PB leprosy (21 out of 25),
which offers an explanation for the lack of increase of anti-PGL-I titers at leprosy diagnosis.
Importantly, in Bangladesh, the percentage of PB cases amongst new leprosy cases is generally
higher than in other countries in Asia, especially southeast Asia where predominantly MB
patients are found[2]. This phenomenon is probably due to a combination of genetic factors as
well as early case detection. Bangladesh is a high endemic area with a high rate of active case-
finding, which leads to a lot of PB cases being found. In contrast, low endemic areas with little
active case-finding have higher numbers of MB cases, since PB is often self-healing. In our
study, only four household contacts developed MB leprosy (out of the 25 total number of new
leprosy patients). PB leprosy in general is characterized by low levels or absence of antibodies
against M. leprae antigens[16], which is in line with our finding that there was no significant
difference in anti-PGL-I Ab level at intake compared to leprosy diagnosis. Schuring et al[24]
found that anti-PGL-I seropositivity was associated with bacterial index (BI). However, most
contacts in our study had PB and therefore an undetectable BI. Separate evaluation of the four
MB patients did not show any differential increase in anti-PGL-I Ab level in this group either.
This is in line with the findings of van Hooij et al[4, 25], showing low levels of anti-PGL-I Ab
in all patients, including MB. Moreover, anti-PGL-I IgM levels could not be used to discrimi-
nate PB patients or household contacts from endemic controls. In leprosy endemic countries
other than Bangladesh, where MB leprosy is more prevalent, the longitudinal pattern of anti-
PGL-I Ab levels could hold more diagnostic value. Besides this, anti-PGL-I antibodies can rep-
resent a useful tool for monitoring effectiveness of treatment of leprosy (reactions), since effec-
tive treatment is associated with decrease in antibody levels[26].
As a part of the COLEP trial, half of the new leprosy contacts received placebo and the
other half single dose rifampicin. It can be expected that single dose rifampicin could lower the
anti-PGL-I antibody level in subjects with a relatively high bacterial load. However, it is
unknown how soon and to which extent the antibody titre is suppressed. Furthermore, there is
also the possibility that subjects become re-infected with M. leprae due to continued exposure
to an unknown source. Also, in the absence of complete ‘sterilisation’ of M. leprae in these sub-
jects, the bacterium may start to multiply again after the effect of rifampicin has waned. So
although the antibody titre may certainly have decreased due to single dose rifampicin, it is
unknown whether this effect would be apparent after 2 years, at the moment of first blood
sampling.
Furthermore, it is worthy to note that leprosy is a complicated disease with different immu-
nological processes playing a role in disease progression, which in turn are affected by factors
such as genetics[27], co-infections[28] as well as food-shortage[29]. The combination of these
factors with the long incubation time that elapses before leprosy becomes clinically manifest,
makes predicting which M. leprae exposed individuals will progress to disease complicated.
For example, certain helminth-derived proteins can bias the host immune response towards
an anti-inflammatory Th2 response, which may facilitate M. leprae growth or progression to
MB leprosy[28]. Furthermore, a period of food shortage can reduce cell mediated immunity of
individuals incubating M. leprae, causing the development of clinical disease[29].
Recent advancements in leprosy biomarker research[15] have shown that IFN-γ responses
measured after stimulation with leprosy-unique antigens can be used as a measure for M.
leprae exposure. In particular, the combination of humoral and cellular biomarkers increased
efficiency to distinguish M. leprae infected from non-infected individuals, patients from con-
tacts, or lepromatous from tuberculoid patients compared to serology alone[4, 15]. In view of
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the findings in this study as well as our previous studies on cellular biomarkers[4, 15, 26, 30],
field-friendly tests using a biomarker signature would improve identification of contacts who
are at risk of developing leprosy as well as asymptomatic, infected individuals who can trans-
mit bacteria. In current longitudinal studies on biomarker identification, a new lateral flow
test format is used (UCP-LFA)[4, 25], that not only allows field-use but also provides a perma-
nent record as the luminescent signal on the LF strips does not fade. Such tests would repre-
sent a useful contribution to current pilot studies on the effectiveness of SDR as leprosy post-
exposure prophylaxis (LPEP)[31], allowing more selective targeting for prophylaxis as well as
preventing overtreatment.
Conclusion
In view of the dichotomy of the leprosy spectrum in terms of immunity against M. leprae, cur-
rent research is focused on identification of predictive biomarker profiles associated with early
stage leprosy, consisting of multiple cellular and humoral (disease-specific) biomarkers. Early
diagnosis of leprosy and subsequent appropriate multidrug therapy (MDT) will not only
decrease severe nerve damage and subsequent lifelong handicaps, but also significantly con-
tribute to further decrease of M. leprae transmission. This study shows that measurement of
anti-PGL-I Abs alone is not sufficient to predict the development of clinical leprosy amongst
household contacts of newly diagnosed leprosy cases in (highly) endemic area such as Bangla-
desh. Because of the high number of PB patients in Bangladesh, using anti-PGL-I titers as a
screening test to discriminate which contacts to treat, may lead us to miss a lot of potential
new cases.
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